Sagimet Biosciences Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
SGMT$10.89+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows (unaudited)
CONDENSED STATE MENTS OF CASH FLOWS
(in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(24,603) | $(28,562) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Accretion of discount on marketable securities, net | (157) | (761) |
| Non-cash operating lease expense | 78 | 77 |
| Stock-based compensation expense | 5,530 | 3,070 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (826) | (722) |
| Accounts payable, accrued expenses and other current liabilities | 401 | 3,339 |
| Operating lease liabilities | (78) | (78) |
| Other assets | (55) | — |
| Net cash used in operating activities | (19,710) | (23,637) |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (46,647) | (58,528) |
| Sales and maturities of marketable securities | 32,843 | 48,651 |
| Net cash used in investing activities | (13,804) | (9,877) |
| Cash flows from financing activities | ||
| Proceeds from sale of Series A common stock | 175,000 | — |
| Payment of issuance costs | (10,800) | — |
| Proceeds from exercise of stock options | 96 | 1 |
| Proceeds from purchases under employee stock purchase plan | 93 | — |
| Net cash provided by financing activities | 164,389 | 1 |
| Net increase (decrease) in cash and cash equivalents | 130,875 | (33,513) |
| Cash and cash equivalents at beginning of period | 35,021 | 75,840 |
| Cash and cash equivalents at end of period | $165,896 | $42,327 |
| Supplemental non-cash investing and financing activities: | ||
| Right-of-use assets obtained in exchange for operating lease obligations | $1,951 | $152 |
| Issuance costs included in accrued expenses and accounts payable | $345 | $— |
| Deferred financing costs within accounts payable and accrued expenses | $25 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.